ACT Reports First Patient Treatment With Telatinib In Phase 2 Clinical Trial
ACT Biotech has reported the treatment of the first patients in a phase 2 clinical trial of Telatinib, in combination with standard-of-care chemotherapy, in the US and Spain.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.